Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Reck

Showing results (211-220 of 437) with videos related to

Pageof 44
Sort By:
Therapeutic Advances in Medical Oncology|May 17, 2021
Afatinib as first-line treatment in patients with <i>EGFR</i>-mutated non-small cell lung cancer in routine clinical practiceWolfgang M Brückl, Martin Reck, Frank Griesinger, et al.
Nature Reviews. Clinical Oncology|July 24, 2023
Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challengesGiannis Mountzios, Jordi Remon, Lizza E L Hendriks, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapyEnriqueta Felip, Federico Rojo, Martin Reck, et al.
Advances in Therapy|March 2, 2025
Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 TrialHorst-Dieter Hummel, Myung-Ju Ahn, Fiona Blackhall, et al.
Clinical Lung Cancer|July 11, 2017
LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural MesotheliomaGiorgio V Scagliotti, Rabab Gaafar, Anna K Nowak, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 25, 2019
Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung CancerMartin Reck, Leora Horn, Silvia Novello, et al.
Cancer|November 8, 2014
Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancerRobert C Doebele, David Spigel, Mustapha Tehfe, et al.
Lung Cancer (Amsterdam, Netherlands)|February 15, 2026
Feasibility and safety of nintedanib in combination with nivolumab in pretreated patients with advanced or metastatic adenocarcinoma of the lung - An AIO phase Ib/II trialMartin Reck, Cornelius Waller, Parvis Sadjadian, et al.
Cancer Treatment Reviews|August 31, 2025
Interpreting immunogenicity in oncology clinical trialsPeter R Galle, Martin Reck, David J Pinato, et al.
Lung Cancer (Amsterdam, Netherlands)|September 30, 2015
Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxelMartin Reck, Anders Mellemgaard, Joachim von Pawel, et al.
Pageof 44

Showing results (211-220 of 437) with videos related to

Sort By:
Pageof 44
Therapeutic Advances in Medical Oncology|May 17, 2021
Afatinib as first-line treatment in patients with <i>EGFR</i>-mutated non-small cell lung cancer in routine clinical practiceWolfgang M Brückl, Martin Reck, Frank Griesinger, et al.
Nature Reviews. Clinical Oncology|July 24, 2023
Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challengesGiannis Mountzios, Jordi Remon, Lizza E L Hendriks, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapyEnriqueta Felip, Federico Rojo, Martin Reck, et al.
Advances in Therapy|March 2, 2025
Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 TrialHorst-Dieter Hummel, Myung-Ju Ahn, Fiona Blackhall, et al.
Clinical Lung Cancer|July 11, 2017
LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural MesotheliomaGiorgio V Scagliotti, Rabab Gaafar, Anna K Nowak, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 25, 2019
Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung CancerMartin Reck, Leora Horn, Silvia Novello, et al.
Cancer|November 8, 2014
Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancerRobert C Doebele, David Spigel, Mustapha Tehfe, et al.
Lung Cancer (Amsterdam, Netherlands)|February 15, 2026
Feasibility and safety of nintedanib in combination with nivolumab in pretreated patients with advanced or metastatic adenocarcinoma of the lung - An AIO phase Ib/II trialMartin Reck, Cornelius Waller, Parvis Sadjadian, et al.
Cancer Treatment Reviews|August 31, 2025
Interpreting immunogenicity in oncology clinical trialsPeter R Galle, Martin Reck, David J Pinato, et al.
Lung Cancer (Amsterdam, Netherlands)|September 30, 2015
Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxelMartin Reck, Anders Mellemgaard, Joachim von Pawel, et al.
Pageof 44